Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34778 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Katharina Frei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Anilides, Pyrimidines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.
Abstract (Originalsprache)
Androgen deprivation therapy (ADT) is the mainstay of the current first‐line treatment concepts for patients with advanced prostate carcinoma (PCa). However, due to treatment failure and recurrence investigation of new targeted therapeutics is urgently needed. In this study, we investigated the suitability of the Cyclin K‐CDK12 complex as a novel therapeutic approach in PCa using the new covalent CDK12/13 inhibitor THZ531. Here we show that THZ531 impairs cellular proliferation, induces apoptosis, and decreases the expression of selected DNA repair genes in PCa cell lines, which is associated with an increasing extent of DNA damage. Furthermore, combination of THZ531 and ADT leads to an increase in these anti‐tumoral effects in androgen‐sensitive PCa cells. The anti‐proliferative and pro‐apoptotic activity of THZ531 in combination with ADT was validated in an ex vivo PCa tissue culture model. In a retrospective immunohistochemical analysis of 300 clinical tissue samples we show that Cyclin K (CycK) but not CDK12 expression correlates with a more aggressive type of PCa. In conclusion, this study demonstrates the clinical relevance of the CycK‐CDK12 complex as a promising target for combinational therapy with ADT in PCa and its importance as a prognostic biomarker for patients with PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Tissue Biobank of the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Department of Urology and Pediatric Urology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
ORCID-Profile: Katrin E Tagscherer
Förderung
- Deutsche Krebshilfe
Zitieren
APA
Frei, K., Schecher, S., Daher, T., Hörner, N., Richter, J., Hildebrand, U., Schindeldecker, M., Witzel, H. R., Tsaur, I., Porubsky, S., Gaida, M. M., Roth, W., & Tagscherer, K. E. (2024). Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34778
Vancouver
Frei K, Schecher S, Daher T, Hörner N, Richter J, Hildebrand U, et al. Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.34778
BibTeX
@article{Frei2024,
author = {Frei, Katharina and Schecher, Sabrina and Daher, Tamas and Hörner, Nina and Richter, Jutta and Hildebrand, Ute and Schindeldecker, Mario and Witzel, Hagen R and Tsaur, Igor and Porubsky, Stefan and Gaida, Matthias M and Roth, Wilfried and Tagscherer, Katrin E},
title = {Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34778}
}
EUVIMED